A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
Фаза 3
Идёт, набор закрыт
NCT06220604
| Заболевание | Plaque Psoriasis |
|---|
| Фаза | Фаза 3 |
|---|
| Спонсор | Janssen Research & Development, LLC |
|---|
| Статус | Идёт, набор закрыт |
|---|
| Участники | 731 участн. |
|---|
| Вмешательство | JNJ-77242113, JNJ-77242113 Matching Placebo, Deucravacitinib, Deucravacitinib Matching Placebo |
|---|
| Дата начала | 9.03.2024 |
|---|
| Дата завершения | 15.11.2024 |
|---|
| Публикация результатов | 25.06.2026 |
|---|
Кратко
The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.
Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater Than or Equal to (>=) 2-Grade Improvement From Baseline at Week 16
Week 16 · Percentage of participants
| Arm 1: Placebo Followed by JNJ-77242113 200 mg | 8.6 Percentage of participants |
|---|
| Arm 2: JNJ-77242113 200 mg | 70.9 Percentage of participants |
|---|
| p-value | <0.001 |
|---|
| Treatment difference | 62.6 (95% CI 53.3–69.5) |
|---|
Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 16
Week 16 · Percentage of participants
| Arm 1: Placebo Followed by JNJ-77242113 200 mg | 1.2 Percentage of participants |
|---|
| Arm 2: JNJ-77242113 200 mg | 57.5 Percentage of participants |
|---|
| p-value | <0.001 |
|---|
| Treatment difference | 56.5 (95% CI 49.0–62.4) |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Другие исследования по этому заболеванию
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.